Biodexa raises $2.3M via warrant exercise agreement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall Street falls as oil rebounds, Middle East tensions simmer
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil up almost 2% as Iran's president vows to never surrender
- On Holding sets 2029 financial targets, authorizes $1B share buyback
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Nasdaq reaches record high close, AI stocks rally
- Elmet Group signs tungsten offtake deal with Hemerdon Mine
- Meta bull case increasingly playing out, Mizuho says
Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds
September 15, 2026 8:00 AM EDTBiodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds
September 15, 2026
Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) (Biodexa or the Company), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced that it has entered into a warrant exercise agreement with an existing accredited investor to exercise certain outstanding warrants to purchase an aggregate of 2,204,218 American Depositary Shares (ADSs) of the Company (the Existing Warrants) at an exercise price of $1.05 for gross cash proceeds of approximately $2.3 million, before deducting financial advisor fees... More
